Therapeutic effect of tyndallized Lactobacillus rhamnosus IDCC 3201 on atopic dermatitis mediated by down-regulation of immunoglobulin E in NC/Nga mice

Microbiol Immunol. 2016 Jul;60(7):468-76. doi: 10.1111/1348-0421.12390.

Abstract

The therapeutic effect of oral administration of Lactobacillus rhamnosus IDCC 3201 tyndallizate (RHT3201) on atopic dermatitis (AD)-like skin lesions in NC/Nga mice were investigated. After induction of dermatitis in NC/Nga mice with house-dust mite extract, each group was fed RHT3201 with 1 × 10(8) , 1 × 10(9) , or 1 × 10(10) cells orally once a day for 8 weeks. Dermatitis scores and frequency of scratching were improved by oral feeding with RHT3201. In contrast to the control group, RHT3201-fed mice showed significantly down-regulated mast cell numbers and serum immunoglobulin E (IgE) concentrations had significantly less IL4 in their axillary lymph node cells. The therapeutic effect of RHT3201 was found to be dose-dependent. These findings indicate that RHT3201 has potential for treating AD.

Keywords: Lactobacillus rhamnosus; atopic dermatitis; immunoglobulin E; tyndallization.

MeSH terms

  • Administration, Oral
  • Animals
  • Biopsy
  • Cytokines / blood
  • Cytokines / metabolism
  • Dermatitis, Atopic / diagnosis
  • Dermatitis, Atopic / immunology*
  • Dermatitis, Atopic / therapy
  • Disease Models, Animal
  • Female
  • Immunoglobulin E / blood
  • Immunoglobulin E / immunology*
  • Immunotherapy
  • Lacticaseibacillus rhamnosus / immunology*
  • Lacticaseibacillus rhamnosus / ultrastructure
  • Lymph Nodes / immunology
  • Lymph Nodes / metabolism
  • Mice
  • Phenotype
  • Probiotics / administration & dosage*

Substances

  • Cytokines
  • Immunoglobulin E